Patent · US Active

Anti-TMEM106B antibodies and methods of use thereof

US11440957B2 · kind B2 · utility

1Cited by

0References

43Claims

0Family size

Assignee

Alector LLC

Inventors

Arnon Rosenthal · Woodside, US
Eric J. Brown · San Francisco, US
Tina SCHWABE · San Francisco, US
Angie Yee · San Francisco, US
Herve Rhinn · New York, US

Key dates

Filing date	Dec 21, 2018
Grant date	Sep 13, 2022
Priority date	—
Expiry date	Dec 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.